BRPI0513706A - anticorpo policlonal recombinante anti-rhesus d e métodos de produção - Google Patents
anticorpo policlonal recombinante anti-rhesus d e métodos de produçãoInfo
- Publication number
- BRPI0513706A BRPI0513706A BRPI0513706-3A BRPI0513706A BRPI0513706A BR PI0513706 A BRPI0513706 A BR PI0513706A BR PI0513706 A BRPI0513706 A BR PI0513706A BR PI0513706 A BRPI0513706 A BR PI0513706A
- Authority
- BR
- Brazil
- Prior art keywords
- rhd
- polyclonal antibody
- collection
- recombinant polyclonal
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPO POLICLONAL RECOMBINANTE ANTI-RHESUS DE MéTODOS DE PRODUçãO. A presente invenção refere-se a um método para produzir uma composição de anticorpo policlonal recombinante anti-RhD (rpAb anti-RhD). O método compreende a obtenção de uma coleção de células transfectadas com uma biblioteca de vetores de expressão de anticorpo anti-RhD, em que cada célula na coleção é capaz de expressar de um segmento de ácido nucléico compreendendo VH e VL, um membro da biblioteca, o qual codifica um membro distinto de composição de anticorpo policlonal recombinante anti-RhD e o qual está localizado no mesmo sítio do genoma de células individuais na referida coleção. As células são cultivadas sob condições estáveis para a expressão do anticorpo policlonal recombinante, o qual é obtida a partir de sobrenadante de células ou de culturas. Os segmentos de ácidos nucléicos que codificam o rpAb anti-RhD são introduzidos nas células por transfecção com uma biblioteca de vetores para a integração sítio-específica. O presente método é adequado para produzir rpAb anti-RhD, tomando dessa forma disponível uma substituição superior de produtos de imunoglobulina profiláticos e terapêuticos derivados de plasma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200401133 | 2004-07-20 | ||
| DKPA200401992 | 2004-12-22 | ||
| PCT/DK2005/000501 WO2006007850A1 (en) | 2004-07-20 | 2005-07-18 | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513706A true BRPI0513706A (pt) | 2008-05-13 |
Family
ID=35159789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513706-3A BRPI0513706A (pt) | 2004-07-20 | 2005-07-18 | anticorpo policlonal recombinante anti-rhesus d e métodos de produção |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8198415B2 (pt) |
| EP (2) | EP1771483A1 (pt) |
| JP (1) | JP4926054B2 (pt) |
| KR (1) | KR20070038556A (pt) |
| AU (1) | AU2005263331B8 (pt) |
| BR (1) | BRPI0513706A (pt) |
| CA (1) | CA2574062A1 (pt) |
| EA (1) | EA014182B1 (pt) |
| IL (1) | IL179658A (pt) |
| MX (1) | MX2007000644A (pt) |
| NO (1) | NO20070927L (pt) |
| NZ (1) | NZ552265A (pt) |
| WO (1) | WO2006007850A1 (pt) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| EA013225B1 (ru) * | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| KR101319848B1 (ko) | 2004-07-20 | 2013-10-18 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법 |
| JP2009518320A (ja) | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
| TW200846362A (en) * | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
| CN101622346A (zh) | 2007-03-01 | 2010-01-06 | 西福根有限公司 | 克隆关联抗体的方法 |
| MX2009008909A (es) * | 2007-03-01 | 2009-08-28 | Symphogen As | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. |
| CA2678628A1 (en) * | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
| JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
| AU2008255383B2 (en) * | 2007-05-25 | 2012-11-01 | Symphogen A/S | Method for manufacturing a recombinant polyclonal protein |
| MX2010002044A (es) * | 2007-09-07 | 2010-03-18 | Symphogen As | Metodos para produccion recombinante de anticuerpos anti-virus sincitial respiratorio (anti-rsv). |
| US20090093004A1 (en) * | 2007-10-04 | 2009-04-09 | Symphogen A/S | Potency assay |
| NZ584684A (en) * | 2007-11-22 | 2012-10-26 | Symphogen As | A method for characterization of a recombinant polyclonal protein |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| TW201920257A (zh) * | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| US20110117605A1 (en) * | 2008-04-23 | 2011-05-19 | Symphogen A/S | Methods for Manufacturing a Polyclonal Protein |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR20110047258A (ko) * | 2008-08-26 | 2011-05-06 | 심포젠 에이/에스 | 저혈소판증의 치료 방법 |
| AU2009287165A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
| WO2010022736A2 (en) | 2008-08-29 | 2010-03-04 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| CN102265152A (zh) * | 2008-10-06 | 2011-11-30 | 西福根有限公司 | 鉴定和选择用于组合药品的药物候选物 |
| FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
| BR112012007815A2 (pt) | 2009-10-09 | 2018-03-20 | Symphogen As | quantificação multiplex de proteínas recombinantes em uma mistura por peptídeos de assinatura e espectrometria de massa. |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| LT2864346T (lt) * | 2012-06-21 | 2019-01-25 | Synthon Biopharmaceuticals B.V. | Antikūnų gryninimo metodas |
| EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| PT3508502T (pt) | 2013-09-20 | 2023-06-22 | Bristol Myers Squibb Co | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores |
| US9683048B2 (en) | 2014-01-24 | 2017-06-20 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| JP6576962B2 (ja) | 2014-03-14 | 2019-09-18 | ノバルティス アーゲー | Ｌａｇ−３に対する抗体分子およびその使用 |
| US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
| WO2016032949A1 (en) | 2014-08-26 | 2016-03-03 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| WO2017184973A1 (en) * | 2016-04-22 | 2017-10-26 | University Of Tennessee Research Foundation | Identifying amyloidogenic proteins & amyloidogenic risk |
| PL3631454T3 (pl) | 2017-05-30 | 2024-01-29 | Bristol-Myers Squibb Company | Leczenie guzów lag-3 pozytywnych |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| CN112513074A (zh) * | 2018-06-22 | 2021-03-16 | 健玛保 | 生产两种或更多种不同抗体的受控混合物的方法 |
| CN112912392B (zh) | 2018-10-26 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 利用重组酶介导的盒式交换的多特异性抗体筛选方法 |
| US12479908B2 (en) | 2019-03-29 | 2025-11-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Antibodies against programmed cell death protein 1 (PD1) and uses thereof |
| EP3947437A1 (en) | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| EP3986925A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| AU2020294879A1 (en) | 2019-06-19 | 2021-12-16 | F. Hoffmann-La Roche Ag | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3140297A1 (en) | 2019-06-19 | 2020-12-24 | Simon Auslaender | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
| WO2020254356A1 (en) | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3140192A1 (en) | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| IL301907A (en) | 2020-10-23 | 2023-06-01 | Bristol Myers Squibb Co | LAG-3 antagonist therapy for lung cancer |
| TW202237642A (zh) * | 2021-01-08 | 2022-10-01 | 美商１０Ｘ基因組學有限公司 | 對冠狀病毒具有特異性的抗原結合多肽及其用途 |
| RU2770654C1 (ru) * | 2021-06-17 | 2022-04-20 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) | Способ профилактики тяжелой формы гемолитической болезни новорожденных при резус-иммунизации у беременных с соматической патологией и потерями плода в анамнезе |
| AU2024328783A1 (en) * | 2023-08-23 | 2026-03-12 | Australian Red Cross Society | Anti-rhesus d human monoclonal antibodies |
| CN119176879B (zh) * | 2024-09-05 | 2025-08-05 | 西安市中心血站（陕西省血液中心） | 一种中和抗d抗体的抗独特型抗体及其应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0162918A1 (en) | 1983-11-28 | 1985-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES |
| US5126130A (en) | 1986-11-24 | 1992-06-30 | The Childrens Hospital Incorporated | Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a |
| GB8722020D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
| GB8722019D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
| GB8722018D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| GB8906129D0 (en) | 1989-03-17 | 1989-05-04 | Central Blood Lab Authority | Pharmaceutical preparations |
| GB8919761D0 (en) | 1989-09-01 | 1989-10-18 | Central Blood Lab Authority | Chemical compounds |
| WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
| CA2116246A1 (en) | 1992-06-26 | 1994-01-06 | Roland Beliard | Human monoclonal anti-rhesus (d) antibodies and cell lines producing same |
| DE69332884T2 (de) | 1992-10-21 | 2003-11-20 | Stefan Miltenyi | Direkte auswahl von zellen durch ein aussheidungsprodukt |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| AU1736495A (en) | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
| FR2724182B1 (fr) | 1994-09-02 | 1996-12-13 | Pasteur Institut | Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| JP3841360B2 (ja) | 1996-06-24 | 2006-11-01 | ツェットエルベー・ベリング・アクチェンゲゼルシャフト | リーサスｄ抗原に対して特異性を有する抗原結合性構造を形成し得るポリペプチド、それらをコードするｄｎａ及びその調製方法並びに使用 |
| US5876925A (en) | 1996-10-11 | 1999-03-02 | The Trustees Of The University Of Pennsylvania | Magnetically activated cell sorting for production of proteins |
| US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| ES2245487T3 (es) | 1997-11-18 | 2006-01-01 | Pioneer Hi-Bred International, Inc. | Composiciones y metodos para la modificacion genetica de plantas. |
| KR100795626B1 (ko) | 1998-07-21 | 2008-01-17 | 코브라 바이오매뉴팩쳐링 피엘씨. | 도처에 있는 염색질 개방 요소(유씨오이)를 포함하는폴리뉴클레오티드 |
| US20020155114A1 (en) | 1998-08-31 | 2002-10-24 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| DK1234022T3 (da) | 1999-07-23 | 2010-07-19 | Univ California | DNA-rekombination i eukaryote celler med bakteriofag PHIC31-rekombinationssystemet |
| EP1106625A1 (en) | 1999-11-17 | 2001-06-13 | ZLB Bioplasma AG | Rhesus D specific peptide sequences |
| MXPA02007771A (es) | 2000-02-08 | 2003-03-10 | Univ Michigan | Mapeo de proteinas. |
| CA2400460C (en) | 2000-02-08 | 2009-01-06 | The Regents Of The University Of Michigan | Mapping of differential display of proteins |
| WO2001058925A2 (en) | 2000-02-08 | 2001-08-16 | The Regents Of The University Of Michigan | Protein separation and display |
| DK1283720T3 (da) | 2000-05-26 | 2007-08-13 | Symphogen As | Rekombinante eller rensede polyklonale antistoffer til behandling af allergi |
| CN1455817A (zh) | 2000-07-21 | 2003-11-12 | (由农业部部长代表的)美利坚合众国 | 用于在真核基因组中置换、转移和富积dna的方法 |
| US6610472B1 (en) | 2000-10-31 | 2003-08-26 | Genetastix Corporation | Assembly and screening of highly complex and fully human antibody repertoire in yeast |
| JP2004514444A (ja) | 2000-11-28 | 2004-05-20 | アプライド モレキュラー エボリューション， インコーポレイテッド | 二重ｌｏｘ組換えに基づく真核生物発現ライブラリーおよび使用方法 |
| ATE475092T1 (de) | 2000-12-26 | 2010-08-15 | Inst Systems Biology | Schnelle und quantitative proteomanalyse und entsprechende verfahren |
| US20040033591A1 (en) | 2002-05-31 | 2004-02-19 | The Regents Of The University Of Michigan | Automated protein analysis system |
| PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
| AU2003284227A1 (en) | 2002-10-15 | 2004-05-04 | The Regents Of The University Of Michigan | Multidimensional protein separation system |
| EA013225B1 (ru) * | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
| US20060275766A1 (en) | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| KR101319848B1 (ko) | 2004-07-20 | 2013-10-18 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법 |
-
2005
- 2005-07-18 BR BRPI0513706-3A patent/BRPI0513706A/pt not_active IP Right Cessation
- 2005-07-18 WO PCT/DK2005/000501 patent/WO2006007850A1/en not_active Ceased
- 2005-07-18 CA CA002574062A patent/CA2574062A1/en not_active Abandoned
- 2005-07-18 NZ NZ552265A patent/NZ552265A/en not_active IP Right Cessation
- 2005-07-18 EA EA200700249A patent/EA014182B1/ru not_active IP Right Cessation
- 2005-07-18 AU AU2005263331A patent/AU2005263331B8/en not_active Ceased
- 2005-07-18 KR KR1020077003955A patent/KR20070038556A/ko not_active Ceased
- 2005-07-18 EP EP05760588A patent/EP1771483A1/en not_active Withdrawn
- 2005-07-18 EP EP08157871A patent/EP1967529A1/en not_active Withdrawn
- 2005-07-18 JP JP2007521793A patent/JP4926054B2/ja not_active Expired - Fee Related
- 2005-07-18 US US11/632,937 patent/US8198415B2/en not_active Expired - Fee Related
- 2005-07-18 MX MX2007000644A patent/MX2007000644A/es active IP Right Grant
-
2006
- 2006-11-28 IL IL179658A patent/IL179658A/en not_active IP Right Cessation
-
2007
- 2007-02-19 NO NO20070927A patent/NO20070927L/no not_active Application Discontinuation
-
2012
- 2012-06-11 US US13/493,623 patent/US20120322690A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL179658A (en) | 2011-08-31 |
| US20120322690A1 (en) | 2012-12-20 |
| EP1771483A1 (en) | 2007-04-11 |
| JP2008509658A (ja) | 2008-04-03 |
| KR20070038556A (ko) | 2007-04-10 |
| AU2005263331A8 (en) | 2011-06-16 |
| AU2005263331B8 (en) | 2011-06-16 |
| NZ552265A (en) | 2009-04-30 |
| CA2574062A1 (en) | 2006-01-26 |
| US8198415B2 (en) | 2012-06-12 |
| EA200700249A1 (ru) | 2007-06-29 |
| EA014182B1 (ru) | 2010-10-29 |
| AU2005263331A1 (en) | 2006-01-26 |
| EP1967529A1 (en) | 2008-09-10 |
| NO20070927L (no) | 2007-04-19 |
| US20090017017A1 (en) | 2009-01-15 |
| WO2006007850A1 (en) | 2006-01-26 |
| IL179658A0 (en) | 2007-05-15 |
| AU2005263331B2 (en) | 2011-05-26 |
| MX2007000644A (es) | 2007-03-28 |
| JP4926054B2 (ja) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513706A (pt) | anticorpo policlonal recombinante anti-rhesus d e métodos de produção | |
| Wu et al. | Membrane engineering-a novel strategy to enhance the production and accumulation of β-carotene in Escherichia coli | |
| BR112021025359A2 (pt) | Composições de proteína anti-vegf e métodos para a produção das mesmas | |
| BRPI0812091A2 (pt) | Método para fabricar uma proteína policlonal recombinante | |
| Jung et al. | Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing | |
| BR112013009275A2 (pt) | glicoformas de anticorpo alfa de receptor anti-folato | |
| BRPI0412138A (pt) | anticorpo, hibridoma, método de produzir um anticorpo, composição farmacêutica, métodos de potencializar a atividade de célula, de detectar a presença de células nk e de purificar de uma amostra células nk, e, composição | |
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| CL2008002349A1 (es) | Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| MX2010002044A (es) | Metodos para produccion recombinante de anticuerpos anti-virus sincitial respiratorio (anti-rsv). | |
| BRPI0924899B8 (pt) | Síntese hmo | |
| BR112012007854A2 (pt) | metodos de produção de glicoproteínas em culturas de células de mamíferos usando glicocorticoides | |
| BR112012007821A2 (pt) | polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos | |
| NZ630568A (en) | Methods and means for the production of ch3 domain-comprising molecules | |
| BRPI0815370B8 (pt) | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica | |
| BR112022000394A2 (pt) | Produção de fucosilactose em células hospedeiras | |
| BRPI0808291A2 (pt) | anticorpos anti-ige/ m1, peptideo, composições, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo anti-ige/m1' apoptótico ou o fragmento funcional, artigo de fabricação, método para depletar espcificamente as células b produtoras de ige, métodos para o tratamento de um doença mediada por ige, para evitar a produção de ige induzida por alérgeno, para reduzir a produção de lge induzida por alérgeno, hibridoma murino, anticorpo e animal transgênico | |
| NZ734307A (en) | Antibodies specific for claudin 6 (cldn6) | |
| WO2012009544A3 (en) | Domain insertion immunoglobulin | |
| BR112019003622A2 (pt) | método para produção de uma proteína de fusão. | |
| Biarnes-Carrera et al. | Orthogonal regulatory circuits for Escherichia coli based on the γ-butyrolactone system of Streptomyces coelicolor | |
| BR112014019277A8 (pt) | Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica | |
| WO2012092376A3 (en) | Comprehensive monoclonal antibody generation | |
| WO2010068897A3 (en) | Stem cell enhanced protein products and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2264 DE 27/05/2014. |